Business
Goldman Sachs Downgrades MoonLake to Sell, Citing Trial Setback and Regulatory Hurdles
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.